How Moderna's CIO helps steer the drugmaker's post-COVID evolution [Fortune]
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: Fortune
“Learning about pharma and biotech was really critical,” says Miller, who had previously been CIO at Capital One, held leadership roles at Mastercard, and spent 17 years in engineering at Amazon and Microsoft. To get up to speed, he read books about drug discovery at the recommendation of Moderna CEO Stéphane Bancel, listened to podcasts, and held “Regulatory 101” sessions with the company's regulatory affairs chief to understand how Moderna's drugs graduated from research to clinical trials, and finally to manufacturing. Miller joined Moderna at an inflection point. With demand for its COVID vaccines slipping, the company has set a goal of introducing up to 15 drugs over a five-year period to treat cancer along with rare and infectious diseases. A respiratory syncytial virus (RSV) shot, which will be Moderna's second drug in the market following its COVID shot that debuted during the pandemic, is poised for a U.S. approval decision by May and will generate $280 million in revenu
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- Ginkgo Bioworks: Buy, Sell, or Hold? [Yahoo! Finance]Yahoo! Finance
- We Think Shareholders May Want To Consider A Review Of Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation Package [Yahoo! Finance]Yahoo! Finance
- WEF Special Meeting Concludes in Riyadh With World Leaders Calling for Clear, Irreversible Path to Peace and Prosperity as Top Global Priority [Yahoo! Finance]Yahoo! Finance
- Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect [Yahoo! Finance]Yahoo! Finance
- mRNA Is Promising A Breakthrough In Fighting Cancer [Yahoo! Finance]Yahoo! Finance
MRNA
Earnings
- 2/22/24 - Beat
MRNA
Sec Filings
- 4/26/24 - Form 4
- 4/24/24 - Form 144
- 4/19/24 - Form 4
- MRNA's page on the SEC website